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Abstract 
Background: It is known that patients with spinocerebellar ataxia (SCA) tend to exhibit 
depressive symptoms. But the pathology of depressive symptoms complicated with SCA, 
including the reaction to the stress resulting from decreased motor function and central 
dysfunction due to neurodegeneration, is controversial and remains to be elucidated. To 
our knowledge, there have been hardly any reports on treatment methods of major 
depressive disorder (MDD) complicated with SCA.  
Case Reports: We report 2 cases in which selective serotonin reuptake inhibitors (SSRIs) 
were effective against MDD complicated with SCA. Interestingly, one of the patients 
developed the symptoms of spinocerebellar degeneration (SCD) during the course of the 
MDD, and the other patient developed the symptoms of MDD during the course of SCA, 
but complete remission of the MDD occurred in both cases. In our cases, the depressive 
symptoms may have been caused mainly by an abnormality of reversible neural 
transmission including serotonin transmission due to central dysfunction, and there is 
the unlikely possibility that the depressive symptoms are reactive to the stress due to 
decreased motor function, because the depressive symptoms decreased with SSRIs.  
Conclusion: Although cerebellar degeneration is irreversible in SCA patients, our cases 
suggest that MDD complicated with SCA may be reversible and treatable using 
antidepressants such as SSRIs with few adverse events. Therefore, it is important for 
neurologists to detect MDD complicated with SCA early and consult a psychiatrist in 
order to improve quality of life of SCA patients. 
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Introduction 
It is known that patients with spinocerebellar ataxia (SCA) tend to exhibit depressive 
symptoms. But there have been hardly any reports regarding treatment of major 
depressive disorder (MDD) complicated with SCA. The side effects of conventional 
antidepressants such as tricyclic antidepressants are attributed to their nonspecific 
interaction with cholinergic, histaminergic, serotonergic, and dopaminergic receptors in 
the central nervous system, and they often cause various adverse events [1]. Therefore, 
antidepressants that do not have this nonspecific interaction, such as the selective 
serotonin reuptake inhibitors (SSRIs), have recently been preferred in the treatment of 
MDD because of their tolerability. Especially in patients with MDD complicated with 
neurodegenerative disease, it seems to be difficult to use antidepressants with a 
nonspecific interaction because of the patients’ central vulnerability and their neurologic 
or autonomic symptoms. SCA consists of a heterogeneous group of neurodegenerative 
disorders. SSRIs seem to be valuable because they cause few adverse events due to their 
specific antidepressant action. We report 2 cases of MDD complicated with SCA who 
successfully responded to SSRIs. 
Case Reports 
Case 1 
The patient is a 53-year-old woman. Her mother was diagnosed with probable SCA at 52 years of age 
and with MDD at 60 years of age. Her mother died at 72 years of age. Her mother’s sister had been 
diagnosed with probable SCA. 
At 49 years of age, the patient developed depressive symptoms, including a severely depressed mood 
in the morning, loss of interest, insomnia, fatigue, and somatic anxiety. She was diagnosed with MDD at 
a psychiatric clinic and treated with fluvoxamine (150 mg/day) and milnacipran (125 mg/day). But the 
depressive symptoms worsened, and anorexia, weight loss (6 kg in 3 months), and suicidal ideation 
ensued. Therefore, at 50 years of age, she was referred to our hospital. No abnormal findings were 
observed on serum examinations, including of thyroid function. Her symptoms met all of the diagnostic 
criteria of DSM-IV for MDD, and her total score on the 17-item Hamilton Rating Scale for Depression 
(HDSR) was 32. Brain magnetic resonance imaging (MRI) showed diffuse atrophy of the cerebellar 
cortex (fig. 1), but there were no clear cerebellar manifestations. She was treated with clomipramine 
(150 mg/day), sulpiride (300 mg/day), and amoxapine (150 mg/day), but treatment was ineffective. At 
51 years of age, the depressive symptoms completely ceased within 3 months after starting paroxetine 
(40 mg/day). She then was able to perform housework without any problems. 
At 52 years of age, she developed lightheadedness on standing, and midodrine (4 mg/day) was 
started. However, the lightheadedness became severer, and she gradually began to experience slurred 
speech and dysphasia. At 54 years of age, she developed a wide-based gait and often fell while walking. 
In addition to predominantly truncal cerebellar ataxia, she was found to have autonomic nervous 
system manifestations (urinary frequency, orthostatic hypotension), pyramidal tract signs (hyperactive 
lower limb tendon reflexes), impaired ocular pursuit movements, limited sursumversion, dysarthria, 
and dysphasia. Head-up tilt test was positive. She was diagnosed with probable SCA. She did not wish to 
undergo genetic diagnosis. Her score on the Mini-Mental State Examination (MMSE) was 22, and her 
full-scale IQ on the Wechsler Adult Intelligence Scale (WAIS)-III was 63, revealing a mild cognitive 
disorder. Though the neurological symptoms gradually progressed, MDD was in remission for 3 years 
after the start of paroxetine. 
Case 2 
The patient is a 37-year-old male. His mother was diagnosed with probable SCA at 40 years of age, 
and she died at 58 years of age. Genetic testing revealed that four of his relatives were positive for SCA3.  
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At 31 years of age, fine movements became difficult. He gradually began to experience 
lightheadedness on standing and diplopia. His gait became wide-based. At 34 years of age, he became 
aware of slurred speech and dysphasia, so he visited our hospital. Cerebellar ataxia of his limbs and 
trunk, autonomic nervous system signs (orthostatic hypotension), pyramidal tract signs (hyperactive 
tendon reflexes in his limbs), impaired ocular pursuit movements, dysarthria, and dysphasia were 
noted. Head-up tilt test was positive and he had an erectile disturbance. MMSE score was 27, but full-
scale IQ on the WAIS-Revised was 66, revealing mild cognitive dysfunction. Brain MRI showed diffuse 
cerebellar atrophy (fig. 1). Analysis of the CAG repeats in the SCA3 locus revealed an expanded allele 
with 69 repeats, and he was diagnosed with SCA3. The symptoms progressed, and at 36 years of age he 
needed a wheelchair. 
At 37 years of age, he developed a severe depressive mood in the morning associated with suicidal 
ideation and lost his appetite and hardly ate anything. His movements became extremely slow, and all 
he could do was lie in bed all day. Blood studies, including of thyroid function, showed no 
abnormalities. The patient fulfilled all of the diagnostic criteria of the DSM-IV for MDD and his total 
score on the HDSR-17 was 30. He was treated with paroxetine (20 mg/day), and moderate improvement 
in the depressive symptoms was observed. But acute urinary retention developed, and paroxetine was 
switched to sertraline (75 mg/day). Subsequently, the urinary retention resolved and the MDD remitted. 
Though the neurological symptoms gradually progressed, MDD was in remission for 1 year after the 
start of sertraline. 
Discussion 
SCA consists of a heterogeneous group of disorders that differ in the extent of the 
neuropathologica involvement of the cerebellum, brainstem, and basal ganglia. Patients 
with degenerative cerebellar diseases tend to exhibit depressive symptoms. A study [2] of 
patients with degenerative cerebellar diseases showed a high prevalence of all mood 
disorders (68%) including MDD (35.5%). Another study [3] showed that the depressive 
symptoms were most common in SCA3 patients (60%), as opposed to 23–27% of patients 
with other types of SCA. 
However, the pathology of depressive symptoms associated with SCA is controversial 
and remains to be elucidated. A direct correlation between Beck Depression Inventory 
scores and motor incapacitation was found in SCA3 patients [4]. Therefore, it was 
concluded that depressive symptoms rather seemed to be reactive than primarily related 
to the disease process itself. 
Yet, an association with central dysfunction due to neurodegeneration and depressive 
symptoms has also been highlighted. It was suggested that the
 greater depressive 
complaints in SCA3 may be due to dysfunction
 of frontal-subcortical circuits in the basal 
ganglia, structures
 that are uniquely involved in SCA3 as opposed to the other subtypes 
[3]. Furthermore, in recent years, there has been emerging evidence suggesting that the 
cerebellum is involved in various psychiatric disorders [5], and the cerebellar 
degeneration may be associated with depressive symptoms. 
In our cases, depressive symptoms may have been caused mainly by an abnormality of 
reversible neural transmission including serotonin transmission due to central 
dysfunction, and there is the unlikely possibility that the depressive symptoms are reactive 
to the stress due to decreased motor function, because the depressive symptoms remitted 
with SSRIs. 
There have been hardly any reports on the treatment of MDD complicated with SCA, 
and the only reports that exist are of a case in which electroconvulsive therapy was 
effective against the catatonic stupor of psychotic depression [6] and a case in which ECT 
was effective against organic catatonia [7].  
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The symptoms of SCA developed during the course of MDD in case 1, and the 
symptoms of MDD developed during the course of SCA in case 2. However, complete 
remission of MDD was achieved with SSRIs in both cases. 
Conclusion 
Although cerebellar degeneration is irreversible in SCA patients, our cases suggest that 
MDD complicated with SCA may be reversible and treatable using antidepressants with 
small adverse events such as SSRIs. Therefore, it is important for neurologists to detect 
MDD complicated with SCA early and consult a psychiatrist in order to improve quality 
of life of SCA patients. 
Patients’ Consent 
Written consent for publication in print and electronically was obtained from the patients. 
 
 
 
 
 
Fig. 1. The cerebellar cortex can be seen to be atrophic on T1-weighted magnetic resonance images 
obtained in case 1 and case 2. 
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